TY - JOUR
T1 - Prevalence, Awareness, and Treatment of Isolated Diastolic Hypertension
T2 - Insights From the China PEACE Million Persons Project
AU - the China PEACE Collaborative Group
AU - Mahajan, Shiwani
AU - Zhang, Danwei
AU - He, Siyun
AU - Lu, Yuan
AU - Gupta, Aakriti
AU - Spatz, Erica S.
AU - Lu, Jiapeng
AU - Huang, Chenxi
AU - Herrin, Jeph
AU - Liu, Shuling
AU - Yang, Jingwei
AU - Wu, Chaoqun
AU - Cui, Jianlan
AU - Zhang, Qiuli
AU - Li, Xi
AU - Nasir, Khurram
AU - Zheng, Xin
AU - Krumholz, Harlan M.
AU - Li, Jing
AU - Dong, Zhong
AU - Jiang, Bo
AU - Zhang, Ying Yi
AU - Liu, Yuhuan
AU - Meng, Yaqing
AU - Xi, Yunfeng
AU - Tian, Yuanmeng
AU - Fu, Yao
AU - Liu, Ting
AU - Yan, Shichun
AU - Jin, Lin
AU - Wang, Jing
AU - Xu, Xiaoling
AU - Xing, Xiuya
AU - Zhang, Luan
AU - Fang, Xin
AU - Xu, Yan
AU - Xu, Chunxiao
AU - Fan, Lei
AU - Qi, Minjie
AU - Qi, Junfeng
AU - Li, Junlin
AU - Liu, Qiong
AU - Feng, Yingqing
AU - Wang, Jiabin
AU - Wen, Hong
AU - Xu, Jie
AU - He, Jun
AU - Jiang, Chenxi
AU - Yang, Cangjiang
AU - Yu, Yue
N1 - Funding Information:
The authors thank all study participants and appreciate the contributions made by project teams at the National Center for Cardiovascular Diseases and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation in the realm of project design and operations. They also thank all provincial and regional officers and research staff for data collection.
Funding Information:
Dr Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the U.S. Food and Drug Administration to develop methods for post‐market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work related to the Cook IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the founder of HugoHealth, a personal health information platform and co‐founder of Refactor Health. Dr Lu is supported by the National Heart, Lung, and Blood Institute (K12HL138037). Dr Gupta is supported by grant T32 HL007854 from the National Heart, Lung and Blood Institute of the National Institutes of Health; is a member of Heartbeat Health, Inc, a preventive cardiology platform; received payment from the Ben C. Martin Law Firm for work related to the Cook IVC filter litigation. The remaining authors have no disclosures to report.
Funding Information:
The National Key Research and Development Program from the Ministry of Science and Technology of China (2018YFC1312400); the Chinese Academy of Medical Sciences Innovation Fund for Medical Science (2016‐I2M‐1‐006); the Major Public Health Service Project from the Ministry of Finance and National Health Commission of China; and the 111 Project from the Ministry of Education of China (B16005).
Publisher Copyright:
© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Background: Characterizing and assessing the prevalence, awareness, and treatment patterns of patients with isolated diastolic hypertension (IDH) can generate new knowledge and highlight opportunities to improve their care. Methods and Results: We used data from the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project, which screened 2 351 035 participants aged 35 to 75 years between 2014 and 2018. IDH was defined as systolic and diastolic blood pressure of <140 and ≥90 mm Hg; awareness as self-reported diagnosis of hypertension; and treatment as current use of antihypertensive medications. Of the 2 310 184 participants included (mean age 55.7 years; 59.5% women); 73 279 (3.2%) had IDH, of whom 63 112 (86.1%) were untreated, and only 6512 (10.3%) of the untreated were aware of having hypertension. When compared with normotensives, participants who were <60 years, men, at least college educated, had body mass index of >28 kg/m2, consumed alcohol, had diabetes mellitus, and prior cardiovascular events were more likely to have IDH (all P<0.01). Among those with IDH, higher likelihood of awareness was associated with increased age, women, college education, body mass index of >28 kg/m2, higher income, diabetes mellitus, prior cardiovascular events, and Central or Eastern region (all P<0.05). Most treated participants with IDH reported taking only 1 class of antihypertensive medication. Conclusions: IDH affects a substantial number of people in China, however, few are aware of having hypertension and most treated participants are poorly managed, which suggests the need to improve the diagnosis and treatment of people with IDH.
AB - Background: Characterizing and assessing the prevalence, awareness, and treatment patterns of patients with isolated diastolic hypertension (IDH) can generate new knowledge and highlight opportunities to improve their care. Methods and Results: We used data from the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project, which screened 2 351 035 participants aged 35 to 75 years between 2014 and 2018. IDH was defined as systolic and diastolic blood pressure of <140 and ≥90 mm Hg; awareness as self-reported diagnosis of hypertension; and treatment as current use of antihypertensive medications. Of the 2 310 184 participants included (mean age 55.7 years; 59.5% women); 73 279 (3.2%) had IDH, of whom 63 112 (86.1%) were untreated, and only 6512 (10.3%) of the untreated were aware of having hypertension. When compared with normotensives, participants who were <60 years, men, at least college educated, had body mass index of >28 kg/m2, consumed alcohol, had diabetes mellitus, and prior cardiovascular events were more likely to have IDH (all P<0.01). Among those with IDH, higher likelihood of awareness was associated with increased age, women, college education, body mass index of >28 kg/m2, higher income, diabetes mellitus, prior cardiovascular events, and Central or Eastern region (all P<0.05). Most treated participants with IDH reported taking only 1 class of antihypertensive medication. Conclusions: IDH affects a substantial number of people in China, however, few are aware of having hypertension and most treated participants are poorly managed, which suggests the need to improve the diagnosis and treatment of people with IDH.
KW - awareness
KW - hypertension subtypes
KW - isolated diastolic hypertension
KW - prevalence
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85072746055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072746055&partnerID=8YFLogxK
U2 - 10.1161/JAHA.119.012954
DO - 10.1161/JAHA.119.012954
M3 - Article
C2 - 31566101
AN - SCOPUS:85072746055
SN - 2047-9980
VL - 8
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 19
M1 - e012954
ER -